Chapter/Section Purchase

1 Study Coverage
1.1 Overactive Bladder Drug Product Introduction
1.2 Global Overactive Bladder Drug Outlook 2017 VS 2022 VS 2028
1.2.1 Global Overactive Bladder Drug Sales in US$ Million for the Year 2017-2028
1.2.2 Global Overactive Bladder Drug Sales in Volume for the Year 2017-2028
1.3 United States Overactive Bladder Drug Outlook 2017 VS 2022 VS 2028
1.3.1 United States Overactive Bladder Drug Sales in US$ Million for the Year 2017-2028
1.3.2 United States Overactive Bladder Drug Sales in Volume for the Year 2017-2028
1.4 Overactive Bladder Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Overactive Bladder Drug in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Overactive Bladder Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Overactive Bladder Drug Market Dynamics
1.5.1 Overactive Bladder Drug Industry Trends
1.5.2 Overactive Bladder Drug Market Drivers
1.5.3 Overactive Bladder Drug Market Challenges
1.5.4 Overactive Bladder Drug Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Overactive Bladder Drug Market Segment by Type
2.1.1 Anticholinergics
2.1.2 Solifenacin
2.1.3 Oxybutynin
2.1.4 Darifenacin
2.1.5 Fesoterodine
2.1.6 Tolterodine
2.1.7 Trospium
2.1.8 Others
2.2 Global Overactive Bladder Drug Market Size by Type
2.2.1 Global Overactive Bladder Drug Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Overactive Bladder Drug Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Overactive Bladder Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Overactive Bladder Drug Market Size by Type
2.3.1 United States Overactive Bladder Drug Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Overactive Bladder Drug Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Overactive Bladder Drug Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Overactive Bladder Drug Market Segment by Application
3.1.1 Idiopathic Bladder Overactivity
3.1.2 Neurogenic Bladder Overactivity
3.2 Global Overactive Bladder Drug Market Size by Application
3.2.1 Global Overactive Bladder Drug Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Overactive Bladder Drug Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Overactive Bladder Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Overactive Bladder Drug Market Size by Application
3.3.1 United States Overactive Bladder Drug Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Overactive Bladder Drug Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Overactive Bladder Drug Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Overactive Bladder Drug Competitor Landscape by Company
4.1 Global Overactive Bladder Drug Market Size by Company
4.1.1 Top Global Overactive Bladder Drug Manufacturers Ranked by Revenue (2021)
4.1.2 Global Overactive Bladder Drug Revenue by Manufacturer (2017-2022)
4.1.3 Global Overactive Bladder Drug Sales by Manufacturer (2017-2022)
4.1.4 Global Overactive Bladder Drug Price by Manufacturer (2017-2022)
4.2 Global Overactive Bladder Drug Concentration Ratio (CR)
4.2.1 Overactive Bladder Drug Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Overactive Bladder Drug in 2021
4.2.3 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Overactive Bladder Drug Manufacturing Base Distribution, Product Type
4.3.1 Global Overactive Bladder Drug Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Overactive Bladder Drug Product Type
4.3.3 Date of International Manufacturers Enter into Overactive Bladder Drug Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Overactive Bladder Drug Market Size by Company
4.5.1 Top Overactive Bladder Drug Players in United States, Ranked by Revenue (2021)
4.5.2 United States Overactive Bladder Drug Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Overactive Bladder Drug Sales by Players (2020, 2021 & 2022)
5 Global Overactive Bladder Drug Market Size by Region
5.1 Global Overactive Bladder Drug Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Overactive Bladder Drug Market Size in Volume by Region (2017-2028)
5.2.1 Global Overactive Bladder Drug Sales in Volume by Region: 2017-2022
5.2.2 Global Overactive Bladder Drug Sales in Volume Forecast by Region (2023-2028)
5.3 Global Overactive Bladder Drug Market Size in Value by Region (2017-2028)
5.3.1 Global Overactive Bladder Drug Sales in Value by Region: 2017-2022
5.3.2 Global Overactive Bladder Drug Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Overactive Bladder Drug Market Size YoY Growth 2017-2028
6.1.2 North America Overactive Bladder Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Overactive Bladder Drug Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Overactive Bladder Drug Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Overactive Bladder Drug Market Size YoY Growth 2017-2028
6.3.2 Europe Overactive Bladder Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Overactive Bladder Drug Market Size YoY Growth 2017-2028
6.4.2 Latin America Overactive Bladder Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Overactive Bladder Drug Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Overactive Bladder Drug Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Astellas Pharma, Inc. (Japan)
7.1.1 Astellas Pharma, Inc. (Japan) Corporation Information
7.1.2 Astellas Pharma, Inc. (Japan) Description and Business Overview
7.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Products Offered
7.1.5 Astellas Pharma, Inc. (Japan) Recent Development
7.2 Pfizer, Inc. (US)
7.2.1 Pfizer, Inc. (US) Corporation Information
7.2.2 Pfizer, Inc. (US) Description and Business Overview
7.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Products Offered
7.2.5 Pfizer, Inc. (US) Recent Development
7.3 Teva Pharmaceutical Industries Limited (Israel)
7.3.1 Teva Pharmaceutical Industries Limited (Israel) Corporation Information
7.3.2 Teva Pharmaceutical Industries Limited (Israel) Description and Business Overview
7.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Products Offered
7.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development
7.4 Allergan, Plc (Ireland)
7.4.1 Allergan, Plc (Ireland) Corporation Information
7.4.2 Allergan, Plc (Ireland) Description and Business Overview
7.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Products Offered
7.4.5 Allergan, Plc (Ireland) Recent Development
7.5 Medtronic plc (Ireland)
7.5.1 Medtronic plc (Ireland) Corporation Information
7.5.2 Medtronic plc (Ireland) Description and Business Overview
7.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Products Offered
7.5.5 Medtronic plc (Ireland) Recent Development
7.6 Mylan N.V. (US)
7.6.1 Mylan N.V. (US) Corporation Information
7.6.2 Mylan N.V. (US) Description and Business Overview
7.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Mylan N.V. (US) Overactive Bladder Drug Products Offered
7.6.5 Mylan N.V. (US) Recent Development
7.7 Endo International plc (Ireland)
7.7.1 Endo International plc (Ireland) Corporation Information
7.7.2 Endo International plc (Ireland) Description and Business Overview
7.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Endo International plc (Ireland) Overactive Bladder Drug Products Offered
7.7.5 Endo International plc (Ireland) Recent Development
7.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
7.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Corporation Information
7.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Description and Business Overview
7.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Products Offered
7.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
7.9 Sanofi (France)
7.9.1 Sanofi (France) Corporation Information
7.9.2 Sanofi (France) Description and Business Overview
7.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Sanofi (France) Overactive Bladder Drug Products Offered
7.9.5 Sanofi (France) Recent Development
7.10 Apotex, Inc. (Canada)
7.10.1 Apotex, Inc. (Canada) Corporation Information
7.10.2 Apotex, Inc. (Canada) Description and Business Overview
7.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Products Offered
7.10.5 Apotex, Inc. (Canada) Recent Development
7.11 Cogentix Medical, Inc. (US)
7.11.1 Cogentix Medical, Inc. (US) Corporation Information
7.11.2 Cogentix Medical, Inc. (US) Description and Business Overview
7.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Products Offered
7.11.5 Cogentix Medical, Inc. (US) Recent Development
7.12 Aurobindo Pharma Limited (India)
7.12.1 Aurobindo Pharma Limited (India) Corporation Information
7.12.2 Aurobindo Pharma Limited (India) Description and Business Overview
7.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Aurobindo Pharma Limited (India) Products Offered
7.12.5 Aurobindo Pharma Limited (India) Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Overactive Bladder Drug Industry Chain Analysis
8.2 Overactive Bladder Drug Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Overactive Bladder Drug Distributors
8.3 Overactive Bladder Drug Production Mode & Process
8.4 Overactive Bladder Drug Sales and Marketing
8.4.1 Overactive Bladder Drug Sales Channels
8.4.2 Overactive Bladder Drug Distributors
8.5 Overactive Bladder Drug Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer